external innovation

Cilcare supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus.

therapeutics

Cilcare Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy.

auditory analytics

Cilcare Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring.

We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.

external innovation

Cilcare supports its partners in the health and life-sciences sector in the development of new therapies to prevent and treat auditory-related diseases including inherited hearing loss, synaptopathy, ototoxicity, sensorineural hearing loss and tinnitus.

therapeutics

Cilcare Therapeutics has forged a portfolio of proprietary drug candidates and co-developed programs, while pioneering an unprecedented clinical approach to developing compounds targeting cochlear synaptopathy.

auditory analytics

Cilcare Auditory Analytics aims to position hearing as a key asset of preventive medicine and global healthcare monitoring.

We aim to utilize patients' auditory measurements to define digital auditory signatures that will serve to characterize different forms of hearing impairments or other pathologies with precision.

cilcare

Making Hearing A Priority

Cilcare is a biotech dedicated to harnessing auditory sciences to reshape the future of care via early diagnosis and targeted treatment. We believe hearing acts as a valuable indicator of our health and must be monitored and preserved accordingly. As awareness of the link between hearing and chronic health conditions grows, auditory sciences are paving the way for the early detection of chronic neurocognitive, inflammatory, and age-related diseases.

Testimonials

What Our Clients Say

CILcare not only enabled us to access high quality specialised auditory pharmacokinetic and efficacy studies with high technical excellence whilst maintaining excellent care and attention to detail and animal welfare, but we also found their scientists not only insightful but also highly collaborative. The CILcare team were flexible and open to changes in protocol as the data from our studies developed and responded positively to time critical activities in highly professional manner. Without access to the studies undertaken at CILcare we would not discovered the novel scientific findings or the opportunity presented by the data from the studies undertaken.
Senior Director, Future Pipeline Discovery, a Top ten pharmaceutical company
CILcare is definitely more than a simple CRO! Following our work experience in PK/PD studies, CILcare now resonates as a trusted partner, fully committed to the success of their Sponsor’s assets. CILcare’s scientific expertise in the auditory system and neurosciences is no longer in doubt. The robustness of CILcare’s animal models, which highly mimic human ear disorders, gives us the confidence for translational success in clinical phases. It is always a pleasure to work with all the team members, they are very proactive, responsive, and dedicated to their customers.
Carmen Herrero, CSO, Spiral Therapeutics
Cilcare played an indispensable role in achieving our goals for our preclinical R&D program. The gifted team members had good communications with us and have proven their highly-valued capability in the execution of ambitious studies by resolving various unexpected challenges. Their expertise and unique technical know-how in otology research enabled us to acquire valuable data to proceed with our program. I would like to thank the entire team for their warm hospitality and the in-depth introduction of their facilities in Montpellier. Cilcare is for us a great partner, which I would recommend to any life science players aiming to create new and reliable drugs to treat ear disorders.
Hiroshi Uchino Ph.D, Senior Researcher, Astellas Pharma Inc.
Autifony has a strong interest in the discovery of new pharmaceutical treatments for hearing disorders, and has unique experience in the preclinical and clinical development of novel treatments for these indications. We recognise Cilcare’s experience in the design and execution of preclinical studies in models of hearing loss. I personally had a great experience working with Aurore; she was very professional and friendly, and she was always available, which helped us to keep within timelines. I was impressed with the overall excellence of the whole team, and would strongly recommend them as a partner.
Nadia Pilati, Ph.D. Senior Electrophysiologist, Autifony Therapeutics Ltd
We relied on the expertise of Cilcare for some of our studies on the neural basis of cochlear implant use (Glennon et al. Nature 2023). The services Cilcare provided enabled us to confirm that our procedures were accurate and appropriate, and the cochleogram data and analysis from Cilcare were of the highest quality. I’m grateful for the diligence and timely services they provided and will definitely work with Cilcare again.
Robert Froemke, PhD, Professor, Department of Otolaryngology-Head and Neck Surgery, NYU Langone Health

cilcare

News

15

Jan

Join Cilcare's experts & CBSET's partner at the ARO 2024 in Anaheim

17

Nov

New publication from Cilcare & Pasteur Institute reveals breakthroughs in mice models' central auditory processing of neurological disorders

14

Nov

Hearing Therapeutics Summit 2023: Watch Cilcare's recorded presentation !

Upcoming

Event Schedule

Feb
27-29
2024

La Jolia

Feb
04-07
2024

Anaheim

ARO

Jan
08-11
2024

San Francisco